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	 Objective	 To	 assess	 the	 immunogenicity	 and	 safety	 of	 human	
papillomavirus–16/18	AS04-adjuvanted	 cervical	 cancer	 vaccine	
in	Chinese	women	aged	18	to	35	years	enrolled	from	Hong	Kong.
	 Design	 Double-blind,	 randomised	 controlled	 trial	 with	 vaccine	 and	
placebo	groups.
	 Setting	 Single-centre	study	in	Hong	Kong.
	 Participants	 Three	hundred	women	enrolled	(150	per	group)	between	March	
2006	and	June	2007.
	 Interventions	 Subjects	 received	 three	 doses	 of	 human	papillomavirus–16/18	
vaccine	 or	 placebo	 (aluminium	 hydroxide),	 administered	
intramuscularly	at	0,	1,	and	6	months.
	Main	outcome	measures	 Human	 papillomavirus–16/18	 seroconversion	 rates	 and	
geometric	mean	titres	at	month	7	(in	human	papillomavirus–16/18	
recipients);	reactogenicity	and	safety	(in	all	subjects).
	 Results	 A	 total	 of	 294	 women	 completed	 the	 study	 (148	 in	 the	
vaccine	group,	146	 in	placebo	group).	All	 initially	seronegative	
subjects	 in	 the	 vaccine	 group	 had	 seroconverted	 for	 human	
papillomavirus–16/18	 antibodies	 by	 month	 7.	 Anti–human	
papillomavirus–16	 and	 anti–human	 papillomavirus–18	
antibody	 geometric	mean	 titres	were	 10 422	 (95%	 confidence	
interval,	 8730-12 442)	 EL.U/mL	 and	 4649	 (3975-5437)	 EL.U/mL,
respectively.	 High	 compliance	 (99%	 in	 both	 groups)	 was	
observed	 for	 the	 three-vaccination	 course.	The	 frequencies	of	
local	 injection	 site	 reactions	 were	 higher	 in	 the	 vaccine	 than	
placebo	group;	pain	being	the	most	common	symptom	in	both	
groups.	Regarding	solicited	symptoms,	fatigue	and	myalgia	were	
the	most	 frequent	 in	both	groups.	Five	 serious	adverse	events	
(four	in	vaccine	group,	one	in	placebo	group)	were	reported,	but	
all	were	considered	unrelated	to	the	vaccinations.
	 Conclusion	 The	 human	 papillomavirus–16/18	 AS04-adjuvanted	 vaccine	
was	highly	 immunogenic,	 safe,	 and	 generally	well	 tolerated	 in	
Chinese	women	from	Hong	Kong.
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Introduction
Cervical cancer is the second most common cancer in women worldwide; the global 
disease burden in 2007 amounting to nearly 555 100 new cases and 309 800 deaths.1 In Hong 
Kong, which has emerged as a new affluent economic area in Asia, cervical cancer was 
reported as the eighth most common cause of cancer-related deaths in women in 2007.2	
According to the Hong Kong Cancer Registry, there were 129 registered cervical cancer 
deaths (accounting for 2.7% of all cancer registered deaths in women) in that year.2 The 
corresponding crude death rate was 3.5/100 000 women and the age-standardised mortality 
rate was reported as 2.3/100 000.2 An opportunistic ‘record and recall’ Cervical Screening 
Programme has been launched in March 2004 by the Hong Kong Department of Health 
in collaboration with health care providers in the public and private sectors. Despite this 
programme, the chance of developing cervical cancer in the lifetime of a Hong Kong 
woman is estimated to be as high as 1 in 104,3 which therefore remains a matter of concern.4
 The causal association between oncogenic human papillomavirus (HPV) infection 
and cervical cancer is well established.5 There are about 200 different HPV types that have 
been identified; 15 of which are considered high-risk types that are associated with	cervical 
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	 目的	 評估以AS04佐劑的人類乳頭瘤病毒-16/18子宮頸癌疫
苗對18至35歲香港華籍婦女的抗體水平和安全性。
	 設計	 以疫苗組和安慰劑組進行雙盲隨機控制測試。
	 安排	 單一機構研究，香港。
	 參與者	 2006年3月至2007年6月期間參與的300名婦女（每組
150人）。
	 干預	 他們於測試開始、1個月和6個月分別接受三針人類
乳頭瘤病毒-16/18疫苗或安慰劑（氫氧化鋁）肌肉注
射。
	主要結果測量	 疫苗組於注射人類乳頭瘤病毒-16/18後7個月的血清轉
化率和幾何平均滴度，以及所有參與者的致反應作用
和安全程度。
	 結果	 共294名婦女（疫苗組148名、安慰劑組146名）完
成研究。疫苗組內所有最初帶血清陰性的婦女於注
射人類乳頭瘤病毒-16/18抗體7個月後均有血清轉換
情況。抗人類乳頭瘤病毒-16和抗人類乳頭瘤病毒-18
抗體的幾何平均滴度分別為10 422（95%置信區
間，8730-12 442）EL.U/mL和4649（3975-5437）
EL.U/mL。研究也顯示參與者於三針療程的高順從性
（兩組均達99%）。較多疫苗組婦女於注射部位出現
局部反應；而疼痛是兩組最常見的症狀。疲勞和肌痛
為兩組最普遍的可預見症狀。5名參與者（疫苗組4
名、安慰劑組1名）出現嚴重不良反應，但全部均與
疫苗接種無關。
	 結論	 以AS04佐劑的人類乳頭瘤病毒-16/18疫苗具高度抗體
水平和安全，且對香港華籍婦女的耐受性也較高。
以AS04佐劑的人類乳頭瘤病毒-16/18子
宮頸癌疫苗對香港華籍婦女的抗體水平和
安全性
cancer. Of the different types identified, HPV-16 and 
-18 are the most common oncogenic types globally,6 
and contribute to over 70% of all invasive cervical 
cancer cases worldwide.7,8 Most of the other high-risk 
types have a phylogenetic relation with either HPV-16 
(-31, -33, -35, -52, and -58) or HPV-18 (-39, -45, -59, and 
-68). The distribution of these oncogenic HPV sero-
types may vary in different parts of the world.9 In Asia, 
HPV-16 and -18 are the most commonly reported in 
women with invasive cervical cancer, followed by 
HPV-58, -33, and -52.10 Previously published studies 
have also confirmed a higher prevalence of HPV-16 
and -18 in Hong Kong Chinese women.11,12
 The cervical cancer burden can be reduced 
by vaccination against certain HPV types. This 
strategy is being rapidly established as the new 
paradigm for cervical cancer prevention. The World 
Health Organization (WHO) recognises cervical 
cancer and other HPV-related diseases as a global 
health problem and recommends the inclusion of 
routine HPV vaccination in national immunisation 
programmes.13 The HPV-16/18 AS04-adjuvanted 
vaccine (Cervarix; GlaxoSmithKline [GSK] Biologicals, 
Rixensart, Belgium) is now licensed in at least 100 
countries worldwide. Large randomised trials have 
demonstrated that the vaccine has a good safety 
profile and high efficacy for reducing high-grade 
cervical intraepithelial neoplasia (CIN) caused by 
HPV-16 and -18.8,14,15 In Hong Kong, the HPV-16/18 
AS04-adjuvanted vaccine was licensed in 2008 for 
women aged 10 to 25 years. While a large amount 
of data is available regarding the immunogenicity, 
safety, and efficacy of this vaccine worldwide, there 
are limited corresponding data available about this 
vaccine’s impact in women from China (including 
Hong Kong).
 This study therefore aimed to evaluate the 
immunogenicity, safety, and reactogenicity of the 
HPV-16/18 AS04-adjuvanted cervical cancer vaccine 
when administered to women of Chinese ethnicity 
residing in Hong Kong.
Methods
Study	design
Healthy women aged 18 to 35 years were enrolled in 
this double-blind, single-centre study conducted in 
Hong Kong after providing written informed consent. 
Subjects were randomised (1:1) to receive either 
the HPV-16/18 AS04-adjuvanted vaccine or placebo. 
Women who were	 receiving any investigational 
or non-registered drug or vaccine were excluded, 
as were those who had	 received AS04-adjuvant or 
HPV vaccine.	 Those having	 a chronic disease (eg 
cancer or autoimmune disorder), or were pregnant, 
breastfeeding or planning to conceive were also 
excluded.
 The study was conducted in accordance with 
Good Clinical Practice guidelines. The study protocol 
was approved by the Independent Ethics Committee 
for an investigational centre (study number: 106001; 
www.clinicaltrials.gov: NCT00306241).
Study	vaccine	composition
Each dose (0.5 mL) of the HPV-16/18 vaccine contained 
20 μg each of HPV-16 and -18 L1 (structural protein of 
HPV) virus-like particle (VLP) and adjuvanted with a 
proprietary AS04 (3-O-desacyl-4’-monophosphoryl 
lipid [50 μg] adsorbed on aluminium hydroxide 
[Al(OH)3, 500 μg]).
 The placebo (manufactured by GSK) consisted 
of 500 μg of aluminium as Al(OH)3 without any viral 
antigen.
 Three doses of either the HPV-16/18 L1 VLP AS04-
adjuvanted vaccine or placebo were administered 
intramuscularly at months 0, 1, and 6. All subjects 
were followed up until month 7.
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Randomisation	sequence	and	allocation
The randomisation of study vaccine or placebo was 
performed at GSK Biologicals, Rixensart, using a 
standard Statistical Analysis System (SAS Institute, 
North Carolina, US) program. The investigator 
was responsible for implementing randomisation 
sequence at the study site. Randomisation was 
performed at two levels:
(1) Randomisation of supplies
 A randomisation list was generated using 
a standard SAS program and was used to 
number the vaccines. Randomisation was 
in blocks (to attain a 1:1 ratio) to achieve a 
balanced treatment allocation throughout the 
study. A single treatment number was used 
for each patient to uniquely identify the doses 
administered to the subject.
(2) Randomisation of subjects
 Age stratification (18-25 years and 26-35 years) 
was used for all the enrolled subjects to ensure 
that an approximately equal number of subjects 
were enrolled in each stratum. Treatment 
allocation was performed at the investigator 
site using a central randomisation system 
on the internet (SBIR). The randomisation 
algorithm used a minimisation procedure upon 
being provided with a subject number and the 
subject’s age in order to determine the subject’s 
treatment number.
 Thus, randomisation was not performed 
separately for the stratified and balanced blocks.
Assessment	of	immunogenicity
Serum samples were collected from subjects pre-
vaccination and at month 7 (ie 1 month post–dose 3) 
to evaluate the antibody response against HPV types 
-16 and -18 using enzyme-linked immunosorbent 
assay (ELISA) [Methodology of MedImmune, UK, 
adapted by GSK Biologicals]. The assay cut-offs for 
anti–HPV-16 and anti–HPV-18 antibodies were 8 ELISA 
units/millilitre (EL.U/mL) and 7 EL.U/mL, respectively.
 Seroconversion/seropositivity rates for anti–
HPV-16 and anti–HPV-18 antibodies were calculated 
with their 95% confidence intervals (CIs). Geometric 
mean antibody titres (GMTs) with 95% CIs and 
the antibody titre ranges were also tabulated. For 
antibody titres below the assay cut-off, an arbitrary 
value of half of the cut-off was used for GMT 
calculations.
Assessment	of	safety	and	reactogenicity
Each subject used diary cards to record solicited local 
symptoms (pain, redness, and swelling at the injection 
site) and solicited general symptoms for 7 days (days 
0-6) following each vaccine dose. Solicited general 
symptoms were fever, headache, fatigue, gastro-
intestinal disturbance (nausea, vomiting, diarrhoea, 
and/or abdominal pain), arthralgia, myalgia, rash, and 
urticaria. The intensity of each adverse event was 
graded on a 3-point scale (from 1 to 3) based on the 
extent of discomfort experienced. Grade 3 (the most 
severe) symptoms were defined as pain preventing 
normal day-to-day activity, redness and swelling over 
part of the body exceeding a diameter of 50 mm, 
fever with an	 axillary temperature of higher than 
39.0°C, urticaria over four	parts of the body, or any 
other general symptoms that interfered	with normal 
activities.
 The percentage of doses followed by solicited 
(local and general) and unsolicited symptoms during 
the 7-day and 30-day follow-up period, respectively 
were calculated with their exact 95% CIs. During the 
entire study period, serious adverse events (SAEs), 
medically significant conditions, pregnancies, and 
new-onset chronic diseases such as asthma, type 1 
diabetes, allergies, and autoimmune disorders were 
recorded. Medically significant conditions were 
defined as events that prompted emergency room 
or physician visits unrelated to common diseases or 
routine visits for physical examination or vaccination. 
New-onset chronic diseases were those based on 
a review of the subject’s pre-vaccination medical 
history.
Statistical	analysis
The primary immunogenicity analysis was performed 
on the according-to-protocol cohort, which included 
subjects who met eligibility criteria, complied with 
protocol-defined procedures, and for whom post-
vaccination assay results were available for antibodies 
against at least one study vaccine antigen. Primary 
analysis of safety was on the total vaccinated cohort 
(ie all subjects who received at least one dose of the 
vaccine).
 A sample size of 120 evaluable subjects was 
required in the vaccine group to demonstrate, with at 
least 92% power, that seroconversion rates obtained 
for HPV-16 and HPV-18 antigens 1 month after the 
complete vaccination course were no less than 
90%. Statistical analysis was performed using Proc 
StatXact 5.0 software (Cytel Software Corporation, 
Massachusetts, US) through SAS.
Results
Demography	and	attrition
Between March 2006 and June 2007, a total of 300 
women were enrolled, randomised into two groups 
(150 each) and vaccinated with at least one dose of 
vaccine or placebo (total vaccinated cohort). All 
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subjects were of Chinese ethnicity and had a mean 
age of 26 (standard deviation, 4) years. Of these, 
294 women completed the study (148 in the vaccine 
group, and 146 in the placebo group) [Fig 1].
Immunogenicity
Baseline serological status (total vaccinated cohort)	
prior to vaccination showed that the majority of 
subjects in the vaccine (76%) and placebo (84%) 
groups were seronegative for both HPV-16 and 
HPV-18 antibodies (Table 1).
 In the according-to-protocol cohort for 
immunogenicity, all	 initially seronegative subjects 
in the vaccine group had seroconverted for both 
anti–HPV-16 and anti–HPV-18 antibodies by month 
7 (Tables 2 and 3). In the placebo group, 2% had 
seroconverted for anti-HPV-16 antibodies	by month 
7 (Tables 2 and 3). Additionally at month 7, respective 
GMTs of 10 422 (95% CI, 8730-12 442) EL.U/mL and 
4649 (95% CI, 3975-5437) EL.U/mL were observed for 
anti–HPV-16 and anti–HPV-18 antibodies in initially 
seronegative subjects in the vaccine group.
 All initially seropositive subjects in the vaccine 
group remained seropositive at month 7 (Tables 2 
and 3). At month 7, seropositive vaccine recipients 
demonstrated anti–HPV-16 and anti–HPV-18 GMTs of 
6511 (95% CI, 4491-9440) EL.U/mL and 4055 (95% CI, 
2981-5514) EL.U/mL, respectively.
Safety	and	reactogenicity
Compliance in returning the filled-in diary card 
(all doses) was high (>99% in both groups). The 
FIG 1. Study participants flowchart
* ATP denotes according-to-protocol
300 Enrolled and vaccinated (total 
vaccinated cohort)
146 Completed the study
1 Consent withdrawal (not due to an adverse 
event)
2 Lost to follow-up (subjects with incomplete 
vaccination course)
1 Lost to follow-up (subjects with complete 
vaccination course)
148 Completed the study
2 Consent withdrawal (not due 
to an adverse event)
150 Assigned to the 
vaccinated group
150 Assigned to the placebo 
group
5 Excluded
1 Administration of vaccine(s) forbidden 
in the protocol
4 Study vaccine dose not administered 
ATP
5 Excluded
3 Administration of vaccine(s) forbidden 
in the protocol
1 Randomisation code broken at the 
investigator site
1 Study vaccine dose not administered 
ATP
39 Excluded
34 Non-compliance with vaccination 
schedule (including wrong and unknown 
dates)
3 Non-compliance with blood sampling 
schedule (including wrong and unknown 
dates)
2 Essential serological data missing
145 ATP* cohort for safety 
analysis
145 ATP cohort for safety 
analysis
44 Excluded
36 Non-compliance with vaccination 
schedule (including wrong and unknown 
dates)
4 Non-compliance with blood sampling 
schedule (including wrong and unknown 
dates)
4 Essential serological data missing
106 ATP cohort for 
immunogenicity analysis
101 ATP cohort for 
immunogenicity analysis
* HPV denotes human papillomavirus, and IgG immunoglobulin G
† Vaccine group = subjects who received the HPV-16/18 L1 virus-like particle AS04-
adjuvanted vaccine; placebo group = subjects who received aluminium hydroxide
Serological status for HPV-16 and 
-18 antibodies*
No. (%) of subjects†
HPV-16 IgG HPV-18 IgG Vaccine group
(n=150) 
Placebo group
(n=150) 
Seropositive Seropositive 9 (6) 3 (2)
Seropositive Seronegative 12 (8) 8 (5)
Seronegative Seropositive 12 (8) 9 (6)
Seronegative Seronegative 114 (76) 126 (84)
Serology not available for at least one 
vaccine antigen 3 (-) 4 (-)
TABLE 1. Baseline serological status (total vaccinated cohort)
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proportion of patients with solicited and unsolicited 
symptoms was generally higher in the vaccine group 
(90% [95% CI, 86-92%] of all administered doses) 
than the placebo group (77% [95% CI, 72-81%] of all 
administered doses) during the 30-day (days 0-29) 
post-vaccination follow-up period.
 The frequencies of solicited local injection site 
symptoms (pain, redness, and swelling) were higher 
in the vaccine than the placebo groups, pain being 
reported most often in both groups; 85% (95% CI, 
81-88%) versus 62% (95% CI, 58-67%), respectively (Fig 
2). Grade 3 pain was reported after 8% of doses	in the 
vaccine group and 1% of doses in the placebo group. 
The mean duration of solicited local symptoms for 
both the vaccine and placebo groups was: pain for 4.0 
days and 2.5 days, redness for 3.3 days and 3.0 days, 
and swelling for 3.6 days and 2.6 days, respectively. In 
the vaccine group, grade	3 redness and swelling were 
reported after 0.5% and 1.8% of doses, respectively, 
with a mean duration of 2.0 days for both symptoms. 
No grade 3 symptoms were reported by patients in 
the placebo group. The range for the mean duration 
of grade 3 symptoms was 2.5 to 4.0 days in both the 
vaccine and placebo groups.
 In all, 97% of the subjects in both groups 
received complete vaccination courses. Fatigue was 
reported after 44% (95% CI, 40-49%) of doses in the 
vaccine group and after 31% (95% CI, 27-36%) in the 
placebo group; corresponding figures for myalgia 
were 40% (95% CI, 35-44%) and 25% (95% CI, 21-30%) 
[Fig 3]. The durations of solicited general symptoms 
during the 7-day (days 0-6) follow-up period were 
similar in both groups. In both groups, grade 3 
solicited general adverse events were infrequent 
(<2%).
 At least one unsolicited symptom was reported 
after 29% (95% CI, 25-35%) of doses in the vaccine 
group and after 22% (95% CI, 18-26%) in the placebo 
group. The most frequently reported unsolicited 
symptom labelled in the Medical Dictionary for 
Regulatory Activities Primary System Organ Class 
was ‘infections and infestations’, after 11% of doses 
in the vaccine group and 9% in the placebo group. 
The symptoms included features of influenza, 
nasopharyngitis, and gastroenteritis. The second 
most common unsolicited group of symptoms 
was related to the nervous system (headache and 
dizziness), reported after 5% of doses in the vaccine 
group and 3% in the placebo group.
 During the entire study period, three patients 
* Vaccine group = subjects who received the HPV-16/18 L1 virus-like particle AS04-adjuvanted vaccine; placebo group = subjects who received aluminium hydroxide 
† Seronegative: subjects with antibody titre <8 EL.U/mL prior to vaccination; seropositive: subjects with antibody titre ≥8 EL.U/mL prior to vaccination
‡ No. of subjects with pre-vaccination results available in each group
§ Percentage of subjects with concentration within specified range
¶ Geometric mean antibody titres (GMT) calculated on all subjects
TABLE 2. Immune response to human papillomavirus (HPV)–16 (according-to-protocol cohort)
Pre-vaccination status/timing No.‡ Antibody titre ≥8 EL.U/mL (95% confidence 
interval)§
GMT (95% confidence interval) 
[EL.U/mL]¶
Vaccine group*
Seronegative†
Pre-vaccination 87 0 (0-4) 4 (4-4)
1 month post–dose 3 87 100 (96-100) 10 422 (8730-12 442)
Seropositive†
Pre-vaccination 18 100 (82-100) 37 (22-61)
1 month post–dose 3 18 100 (82-100) 6511 (4491-9440)
Total
Pre-vaccination 105 17 (11-26) 6 (5-7)
1 month post–dose 3 105 100 (97-100) 9614 (8182-11 297)
Placebo group*
Seronegative†
Pre-vaccination 90 0 (0-4) 4 (4-4)
1 month post–dose 3 90 2 (0.3-8) 4 (4-5)
Seropositive†
Pre-vaccination 10 100 (69-100) 30 (15-58)
1 month post–dose 3 10 90 (56-100) 21 (9-46)
Total
Pre-vaccination 100 10 (5-18) 5 (4-6)
1 month post–dose 3 100 11 (6-19) 5 (4-6)
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* Vaccine group = subjects who received the HPV-16/18 L1 virus-like particle AS04-adjuvanted vaccine; placebo group = subjects who received aluminium hydroxide 
† Seronegative: subjects with antibody titre <7 EL.U/mL prior to vaccination; seropositive: subjects with antibody titre ≥7 EL.U/mL prior to vaccination
‡ No. of subjects with pre-vaccination results available in each group
§ Percentage of subjects with concentration within specified range
¶ Geometric mean antibody titres (GMT) calculated on all subjects
TABLE 3. Immune response to human papillomavirus (HPV)–18 (according-to-protocol cohort)
Pre-vaccination status/timing No.‡ Antibody titre ≥7 EL.U/mL (95% confidence 
interval)§
GMT (95% confidence interval) 
[EL.U/mL]¶
Vaccine group*
Seronegative†
Pre-vaccination 88 0 (0-4) 4 (4-4)
1 month post–dose 3 88 100 (96-100) 4649 (3975-5437)
Seropositive†
Pre-vaccination 16 100 (79-100) 15 (11-22)
1 month post–dose 3 16 100 (79-100) 4055 (2981-5514)
Total
Pre-vaccination 104 15 (9-24) 4 (4-5)
1 month post–dose 3 104 100 (97-100) 4552 (3960-5232)
Placebo group*
Seronegative†
Pre-vaccination 90 0 (0-4) 4 (4-4)
1 month post–dose 3 89 3 (1-10) 4 (4-4)
Seropositive†
Pre-vaccination 8 100 (63-100) 24 (12-48)
1 month post–dose 3 8 75 (35-97) 23 (7-79)
Total
Pre-vaccination 98 8 (4-16) 4 (4-5)
1 month post–dose 3 97 9 (4-17) 4 (4-5)
in the vaccine group had four SAEs (abdominal pain, 
irritable bowel syndrome, dizziness, and headache), 
and one patient in the placebo group had an SAE 
(pelvic inflammatory disease). All five SAEs were 
considered to be unrelated to the injections, and 
there was no fatality.
 Medically significant conditions were reported 
by 28% (95% CI, 21-36%) and 16% (95% CI, 11-23%) 
of the subjects in the vaccine and placebo groups, 
respectively. In all, 12 subjects reported at least one 
new-onset chronic disease based on GSK assessment; 
5% (95% CI, 2-10%) in the vaccine group and 3% (95% 
CI, 0.7-7%) in the placebo group. Four pregnancies 
were reported during the entire study period (two 
in each group). One pregnancy in the vaccine 
group resulted in a normal birth and a healthy child, 
while the other three pregnancies were interrupted 
(elective abortions) due to personal/socio-economic 
reasons.
Discussion
The burden of cervical cancer remains moderately 
high in Hong Kong, in contrast to other economically 
comparable western countries.4 Presently available 
cervical cancer prevalence data for women and 
young adolescent girls in Hong Kong may be 
FIG 2.  Overall frequency of solicited local symptoms during days 0-6 post-vaccination 
(total vaccinated cohort)
Error bars represent 95% confidence intervals
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insufficient to advocate widespread introduction 
of HPV vaccination.16 Data with this vaccine are 
available from numerous countries, but are limited 
for women of Chinese ethnicity. This study, which 
was conducted to evaluate immunogenicity, safety, 
and reactogenicity of the HPV-16/18 AS04-adjuvanted 
cervical cancer vaccine in Hong Kong Chinese 
women, helps address	this issue to some extent.
 Before vaccination, the majority of women in 
our study were seronegative for both HPV-16 and -18 
antibodies. All initially seronegative women in the 
vaccine group seroconverted to both antigens with 
high GMT levels. Similar high immune responses 
were also observed in all initially seropositive 
subjects in the vaccine group. This indicates that 
prior exposure to natural infection with HPV does 
not affect the immune response generated by the 
HPV-16/18 cervical cancer vaccine. Also the high GMT 
levels in initially seropositive women are important 
as natural infection may not guarantee protection 
against re-infection or confer	 sufficient long-term 
protection.17,18 Prophylactic vaccination with the 
HPV-16/18 AS04-adjuvanted cervical cancer vaccine 
may help protect women from developing cervical 
cancer, by inducing sustained antibody responses. 
In the global clinical programme, this vaccine has 
demonstrated immune responses to both vaccine 
antigens that persist up to 7.3 years,19 at levels 
substantially higher than those induced by natural 
infection. The unique AS04-adjuvant system used 
in this formulation might play an important role in 
inducing high and persistent antibody titres and may 
even induce a degree of cell-mediated immunity.20 
In a previous study, this AS04-adjuvant formulation 
was observed to be immunologically superior to the 
same antigens adjuvanted with aluminium alone.20
 Women in our study (aged 18-35 years) exhibited 
a vaccine response comparable to that reported in 
other large global efficacy studies (of women aged 
15-25 years) in which efficacy against HPV-16/18 
infection and CIN 2+ has been confirmed.21,22 Also, the 
results in our cohort were in line with those in another 
phase III trial where the vaccine was immunogenic in 
women aged	 15 to 55 years.23 As in other countries 
where efficacy trials have shown favourable results, 
our study suggests that the vaccine may also confer 
similar clinical efficacy in reducing HPV infections 
and CIN lesions in Hong Kong.
 This study also showed that the vaccine was 
generally well tolerated in our local population, 
though some injection site symptoms and solicited 
general symptoms (fatigue and myalgia) were more 
common in the vaccine group than in the controls, 
which was also consistent with previously reported 
findings.21,24 Women remained very compliant, 
indicating that side-effects	did not prevent successful 
completion of vaccination courses.
 Our results suggest that HPV vaccination may 
be as effective in cervical cancer prevention in Hong 
Kong as in other countries worldwide. According to 
the WHO, the largest impact of HPV vaccination is 
expected to result from targeting young adolescent 
girls before they become sexually active.13 Unlike 
countries such as UK and Australia where a national 
immunisation programme against HPV is in place 
for adolescent girls, in Hong Kong vaccination is 
mainly opportunistic, and women have to pay for the 
vaccine. Experience from cervical cytology screening 
programmes suggest that an opportunistic system 
is likely to benefit only a limited, low-risk group 
within the population. Thus, whilst over 60% of 
Hong Kong women have had cervical smears,3 only 
20% of women aged more than 60 years have been 
tested.25 Likewise, without a population vaccination 
programme, a low uptake is to be expected from 
‘opportunistic vaccination’. While the vaccine 
would confer most protection when administered 
to women who have never been exposed to the 
virus (ie before they become sexually active), the 
majority of local women believe that only those 
who are sexually active should be vaccinated.26 Thus, 
despite the high efficacy and availability of the study 
vaccine in Hong Kong, without effective measures to 
correct misconceptions about HPV vaccination and	
target women before sexual exposure, availability of 
vaccination is unlikely to yield a significant reduction 
in cervical cancer.
 Previous studies in our population suggested 
FIG 3.  Overall frequency of solicited general symptoms during days 0-6 post-
vaccination (total vaccinated cohort)*
Error bars represent 95% confidence intervals
* Grade 3 solicited general symptoms (being <2.0%) were rarely reported in either 
group
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that despite largely inadequate knowledge on cervical 
cancer and HPV infection, the acceptability of the 
cervical cancer vaccine was high.26 Findings from this 
study demonstrated that the vaccine was generally 
well tolerated and effective in generating an immune 
response, which provides reassuring information 
for women considering such prophylaxis. Details 
about side-effects and their likely time frame could 
help women develop realistic expectations. Data 
from this study may also provide a scientific basis for 
consideration of a population-wide cervical cancer 
vaccination programme for Hong Kong in the future.
 In conclusion, the present study confirms that 
the HPV-16/18 AS04-adjuvanted vaccine is highly 
immunogenic and generally well tolerated in 18-to-35-
year-old Hong Kong Chinese women. Together with 
an improved cervical cancer screening programme, 
HPV vaccination promises to significantly reduce this 
cancer disease burden in Hong Kong.
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